SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today addressed recent claims by a purported research firm known for fueling and participating in short-selling, which has distributed false and incomplete information about the company in an apparent effort to profit by driving down the company’s stock price.
“Our team at Know Labs remains highly confident in the ability of our Bio-RFID platform technology to detect and measure glucose and other analytes in the body non-invasively, at extremely high levels of accuracy,” said Ron Erickson, Know Labs founder and chairman. “We continue to test and refine our technology while working toward the FDA clearance process for medical-grade diagnostic devices.”
Know Labs will report its fourth quarter and fiscal year 2022 results during an audio webcast today, Dec. 20, 2022. This follows a recent presentation to institutional investors at the Bernstein CGM Disruptors Conference last month.
“Attempts to manipulate the capital markets by self-interested actors seeking short-term profits by spreading lies disguised as equities research are reprehensible,” Erickson continued. “White Diamond Research is notorious for its smear campaigns. Their required legal disclosure makes its intentions clear: ‘You should assume that as of the publication date of our reports and research, White Diamond (possibly along with or through our members, partners, affiliates,...
Over the last year, beyond traditional healthcare and federal procurement matters, the government has pursued federal False Claims Act (FCA) investigations and enforcement across high-risk areas, i...